Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 15;19:140. doi: 10.1186/s12882-018-0940-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 4 — MCU antagonist prevented podocytes from ADR- and Ang II-induced apoptosis in vitro. Ctl, control; ADR, Adriamycin; Ang II, angiotensin II; Ru360, MCU inhibitor; a, compared with Ctl group; b, compared with the ADR or Ang II group; *, P < 0.05; **, P < 0.01. a The cells in Q3 which were annexin high and PI low were counted as apoptotic cells. Compared with ADR or Ang II -treated podocytes, Ru360 decreased the podocyte apoptosis rate significantly (n = 3). b Compared with ADR or Ang II -treated podocytes, Ru360 decreased active caspase-3 in mouse podocytes significantly (n = 4). c Compared with ADR or Ang II -treated podocytes, Ru360 decreased mitochondrial Ca²⁺ levels in mouse podocytes significantly (n = 10)